Ignore This Picture
Spacer
faculty photo

Mark T. Osterman, MD, MSCE

Associate Professor of Medicine at the Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia
Attending Physician, Penn Medicine at Radnor
Attending Physician, Hospital of the University of Pennsylvania
Attending Physician, Penn Presbyterian Medical Center
Director, IBD Journal Club, University of Pennsylvania Perelman School of Medicine
Director, Remicade Infusion Center, Penn Medicine at Radnor
Associate Director, Inflammatory Bowel Disease Center Research, University of Pennsylvania Perelman School of Medicine
Department: Medicine

Contact information
Penn Presbyterian Medical Center
Division of Gastroenterology
218 Wright-Saunders Building
51 North 39th Street
Philadelphia, PA 19104
Office: 215-662-8900
Fax: 215-662-0950
Education:
BA (Chemistry)
Harvard University, 1995.
MD (Medicine)
Harvard Medical School, 1999.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2005.
Post-Graduate Training
Intern in Internal Medicine, Brigham and Women's Hospital, 1999-2000.
Resident in Internal Medicine, Brigham and Women's Hospital, 2000-2002.
Fellow in Gastroenterology, University of Pennsylvania, 2002-2005.
Fellow in Clinical Epidemiology and Biostatistics, University of Pennsylvania, 2003-2005.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Lewis JD, Scott F, Brensinger CM, Roy JA, Osterman MT, Mamtani R, Chen L, Yun Huifeng, Xie F, Curtis JR: Reduced mortality rates with anti-tumor necrosis factor alpha directed therapy when compared to prolonged corticosteroid therapy for inflammatory bowel disease. Gastroenterology 2017 Notes: Oral presentation at annual Digestive Diseases Week meeting May 2017.

Lewis JD, Scott FI, Brensinger CM, Roy JA, Osterman MT, Mamtani R, Bewtra M, Chen L, Yun H, Xie F, Curtis JR: Increased mortality rates with prolonged corticosteroid therapy when compared to anti-tumor necrosis factor alpha therapy for inflammatory bowel disease. American Journal of Gastroenterology 2017 Notes: In press.

Osterman MT, Lichtenstein GR: Infliximab vs. Adalimumab for UC: Is There a Difference? Clinical Gastroenterology and Hepatology 15: 1197-9, 2017.

Osterman MT, Foley C, Matthias I: Clozapine-induced acute gastrointestinal necrosis: a case report. Journal of Medical Case Reports 11: 270, 2017.

Osterman MT: Ready or not, here they are: Anti-TNF biosimilars for IBD. AGA Perspectives 13: 12-3, 2017.

Vajravelu R, Osterman MT, Aberra FN, Roy JA, Lichtenstein GR, Mamtani R, Goldberg DS, Lewis JD, Scott FI: Indeterminate quantiFERON-TB gold increases likelihood of inflammatory bowel disease treatment delay and hospitalization. Inflammatory Bowel Diseases 2017 Notes: In press.

Lewis JD, Bewtra M, Scott FI, Brensinger CM, Reed SD, Roy JA, Osterman MT, Mamtani R, Chen L, Yun H, Xie F, Gilroy E, Sandler RS, Chen W, Curtis JR, Johnson R: Patient valued comparative effectiveness of tumor necrosis factor alpha inhibitors and corticosteroids for inflammatory bowel disease. www.pcori.org 2017 Notes: In press.

Osterman MT, Lichtenstein GR: Infliximab vs. Adalimumab for UC: Is There a Difference? Clinical Gastroenterology and Hepatology 2017 Notes: In press.

Papamichael K, Chachu KA, Vajravelu R, Vaughn BP, Ni J, Cheifetz AS, Osterman MT: Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared to reactive monitoring of serum concentrations of infliximab. Clinical Gastroenterology and Hepatology 15: 1580-8, 2017.

Cross RK, Osterman MT, Panaccione R, Afzali A, Song X, Shi N, Ding Y, Wang A: The Incidence of Cardiovascular Events in Patients with Crohn's Disease Treated with Vedolizumab and Anti-TNF Therapies. Gastroenterology 2017 Notes: Poster presentation for annual Digestive Diseases Week meeting, Chicago IL, May 2017.

back to top
Last updated: 12/11/2017
The Trustees of the University of Pennsylvania
 
Spacer

[Return to faculty list]

Spacer
University of Pennsylvania | School of Medicine